Volume 96 Issue 5 | p. 15 | Concentrates
Issue Date: January 29, 2018

Skyhawk launches to target RNA

By Ryan Cross
Department: Business
Keywords: Start-ups, RNA, Skyhawk Therapeutics, RNA small molecules, Skyhawk, exon skipping

Excitement over targeting RNA with small molecules continues with the launch of Skyhawk Therapeutics. The Waltham, Mass.-based start-up raised $8 million in seed funding to make compounds that target binding pockets in RNA splicing machinery to treat conditions caused by exon skipping, a process in which shortened versions of RNA are produced. Drugs that fix exon skipping and restore production of RNA have gained attention in clinical trials for spinal muscular atrophy. Skyhawk plans to file an Investigational New Drug Application for a cancer compound by the end of 2018.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment